ZS Pharma (ZSPH) Posts Q4 Loss of 98c/Share

ZS Pharma (NASDAQ: ZSPH) reported Q4 EPS of ($0.98), $0.23 worse than the analyst estimate of ($0.75).

"We made significant progress with ZS-9 last year including the publication of our Phase 3 trials in JAMA and NEJM highlighting the interest from the medical community in hyperkalemia and in ZS-9," said Robert Alexander, Ph.D., chief executive officer of ZS Pharma. "As we approach the submission of our NDA in the second quarter of this year, we believe that we have the most robust and comprehensive clinical trial program addressing acute and chronic hyperkalemia."

For earnings history and earnings-related data on ZS Pharma (ZSPH) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Paychex beats fourth quarter EPS estimates, stock slides
• Currenc Group suspends Indonesian WalletKu unit operations